Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04617795 · ClinicalTrials.gov registry record · NA
Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes
A NA study, sponsored by Insulet Corporation.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT04617795 is a NA study that has completed, run by Insulet Corporation. The registered enrollment target is 25 participants.
The verdict
NCT04617795, a NA study, has completed, sponsored by Insulet Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The study subjects will be separated into 2 groups, depending on their previous insulin therapy with approximately 50% of subjects from each group, continuous glucose monitoring (CGM) naive. Group A will complete a 2-week Standard Therapy Phase followed by 8 weeks of Omnipod 5 system use. Group B will complete a 2-week Standard Therapy Phase followed by 10 weeks of Omnipod 5 system use. Group A and Group B will have an optional 6-month extension of Omnipod 5 system use
Interventions
- DEVICE Omnipod 5 Automated Insulin Delivery System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2022-03-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04617795
The ClinicalTrials.gov registry entry for NCT04617795 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insulet Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Omnipod 5 Automated Insulin Delivery System is the first listed.
NCT04617795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04617795 about?
NCT04617795 is a clinical study titled "Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes". The study subjects will be separated into 2 groups, depending on their previous insulin therapy with approximately 50% of subjects from each group, continuous glucose monitoring (CGM) naive. Group A will complete a 2-week Standard Therapy Phase followed by 8 weeks of Omnipod 5 system use. Group B ...
What is the current status of trial NCT04617795?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2020-11-23. Estimated completion is 2022-03-06.
What interventions are being tested in trial NCT04617795?
The interventions under investigation include: Omnipod 5 Automated Insulin Delivery System (DEVICE).
Who is sponsoring clinical trial NCT04617795?
This trial is sponsored by Insulet Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.